Tel Aviv, Israel

Mordechai Erez

USPTO Granted Patents = 1 

Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2005

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovator Mordechai Erez: Pioneering Antiarrhythmic Compounds

Introduction: Mordechai Erez, an innovative inventor based in Tel Aviv, Israel, has made significant contributions to the field of medicine through his patented work on tricyclic compounds. With a focus on therapeutic uses, his invention presents promising advancements in the treatment of arrhythmias.

Latest Patents: Erez holds one patent titled "Tricyclic compounds and their uses as antiarrhythmic antifibrillatory and defibrillatory agents." This patent outlines a compound characterized by a general formula that includes various structural components, allowing it to act as an effective defibrillating and anti-fibrillatory agent. These novel compounds and their pharmaceutically acceptable salts hold potential as treatments for anti-arrhythmic and anti-ischemic conditions.

Career Highlights: Mordechai Erez is affiliated with the Technion Research and Development Foundation Limited, where he continues to develop his research and innovations. His academic and professional background has equipped him with the expertise to tackle complex challenges in drug development and therapeutic applications.

Collaborations: Throughout his career, Erez has collaborated with notable coworkers including Ofra Levy and Ehud Keinan. Their joint efforts have facilitated advancements in their research, leading to significant contributions in their respective fields.

Conclusion: Mordechai Erez is a distinguished inventor whose work on tricyclic compounds represents a critical advancement in antiarrhythmic therapies. As the field of medicine evolves, his contributions may play a pivotal role in enhancing patient care and therapeutic outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…